Michael Marino, NuPathe, Inc.

NuPathe Inc. CEO Jane H. Hollingsworth was quoted as saying in a press release: ''Michael brings a strong mix of legal, business, and management experience to NuPathe. We are delighted to welcome Michael to the management team and look forward to his contributions.''

Mr. Marino has over nine years of experience with top law firms. Prior to joining NuPathe, he was a Senior Associate in the Corporate Law Department at Morgan, Lewis and Bockius LLP, in Philadelphia, PA. While there, he advised both public and private companies in connection with securities offerings, financings, mergers and acquisitions, strategic partnerships, SEC compliance, corporate governance, and other corporate matters. Prior to Morgan, Lewis and Bockius, Mr. Marino was an Associate in the Corporate Law Department at WilmerHale LLP in Boston, MA and an auditor at Arthur Andersen LLP.

Mr. Marino earned a B.S. in Accountancy from Villanova University and his J.D. from Boston College Law School.

NuPathe Inc. is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, Zelrix(TM), is a transdermal patch for the treatment of migraine.

In addition, NuPathe has two other proprietary product candidates in preclinical development that address large market opportunities: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.